Composite measures in psoriatic arthritis: GRAPPA 2008
- PMID: 20147481
- DOI: 10.3899/jrheum.090956
Composite measures in psoriatic arthritis: GRAPPA 2008
Abstract
At the 2008 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) in Leeds, UK, members discussed the value and current status of composite measures for the assessment of psoriatic arthritis (PsA). In plenary presentations, examples of composite measures developed for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) were reviewed, followed by a presentation of the assessment of disease activity in systemic lupus erythematosus. Three recently devised composite methods of assessing activity or response in PsA also were presented. Considerable discussion followed in breakout groups, and members agreed that a new composite measure specifically for PsA is necessary. The composite measure should include components that encompass the spectrum of psoriatic disease, i.e., in addition to assessment of peripheral joints, it should include assessment of sacroiliitis, spondylitis, enthesitis, and dactylitis, as well as skin and nail disease.
Similar articles
-
Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting.J Rheumatol. 2011 Mar;38(3):540-5. doi: 10.3899/jrheum.101116. J Rheumatol. 2011. PMID: 21362782
-
Psoriasis and Psoriatic Arthritis Video Project 2010: a report from the GRAPPA annual meeting.J Rheumatol. 2011 Mar;38(3):562-3. doi: 10.3899/jrheum.101122. J Rheumatol. 2011. PMID: 21362788
-
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2008.J Rheumatol. 2010 Feb;37(2):446-7. doi: 10.3899/jrheum.090954. J Rheumatol. 2010. PMID: 20147479
-
Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.J Rheumatol. 2011 Jul;38(7):1496-501. doi: 10.3899/jrheum.110278. J Rheumatol. 2011. PMID: 21724722
-
A review of disease activity measures for psoriatic arthritis: what is the best approach?Expert Rev Clin Immunol. 2014 Sep;10(9):1241-54. doi: 10.1586/1744666X.2014.943663. Epub 2014 Aug 4. Expert Rev Clin Immunol. 2014. PMID: 25088300 Review.
Cited by
-
Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.Clin Rheumatol. 2017 Sep;36(9):2045-2054. doi: 10.1007/s10067-017-3578-9. Epub 2017 Feb 25. Clin Rheumatol. 2017. PMID: 28238086 Free PMC article.
-
Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion.Rheumatol Int. 2024 Nov;44(11):2327-2336. doi: 10.1007/s00296-024-05644-y. Epub 2024 Jul 6. Rheumatol Int. 2024. PMID: 38969942 Review.
-
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.Rheumatology (Oxford). 2012 Aug;51(8):1368-77. doi: 10.1093/rheumatology/kes001. Epub 2012 Feb 17. Rheumatology (Oxford). 2012. PMID: 22344575 Free PMC article. Clinical Trial.
-
Spondyloarthritides: evolving therapies.Arthritis Res Ther. 2010;12(6):221. doi: 10.1186/ar3178. Epub 2010 Dec 17. Arthritis Res Ther. 2010. PMID: 21205283 Free PMC article. Review.
-
Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis.Clin Cosmet Investig Dermatol. 2017 May 8;10:155-163. doi: 10.2147/CCID.S124886. eCollection 2017. Clin Cosmet Investig Dermatol. 2017. PMID: 28507445 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous